Brain disease drug developer Neumora Therapeutics received a $100 million equity investment from U.S. biotech firm Amgen Inc. As a result, Neumora will receive global rights to produce and distribute some of Amgen’s experimental drugs aimed at neurodegenerative diseases.
Together with the $400 million that the company raised from investors such as SoftBank Vision Fund, this investment will enable Neumora to develop precision medicines for complex brain diseases. Currently, such medicines exist in the field of cancer treatments.
“Traditional neuroscience R&D is constrained by a ‘one-size-fits-all’ treatment approach, often leading to underwhelming efficacy, high placebo response, and routine clinical trial failures,” Neumora co-founder Kristina Burow explained. “Patients deserve better.”
Amgen decided to end its own ventures into the development of neuroscience drugs, rather than choosing to allow genetics to take over the process. Neumora, however, will continue its neuroscience efforts.
Led by ARCH Venture Partners, Neumora’s series A funding round included investors such as SoftBank, Alexandria Venture Investments, and Altitude Life Science Ventures.
